Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20 p.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

A webcast replay will be available approximately 48-hrs after the live webcast.

Investor:
RA-JJCUS-InvestorRel@ITS.JNJ.com

Media:
media-relations@its.jnj.com

News Provided by Business Wire via QuoteMedia

JNJ
The Conversation (0)
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotments, if any. Kenvue's common stock has been approved for listing on the New York Stock Exchange under the symbol "KVUE" and is expected to begin trading on May 4, 2023. The IPO is expected to close on May 8, 2023, subject to the satisfaction or waiver of customary closing conditions.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ).

As quoted in the press release:

Keep reading...Show less

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech.

As quoted in the press release:

Keep reading...Show less
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With global spending on medicine using list prices growing by 38 percent over the past five years and a forecasted increase of 35 percent through 2029, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded the scope of the contract to include all of Maccabi's pharmacies and additional nurses. Maccabi is the second largest Healthcare Management Organization ("HMO") in Israel, serving over 2.6 million Israelis and is renowned for its use of technology and emphasis on patient-centered care, according to Maccabi's website here.

Pursuant to the amended agreement, Seegnal will continue to deliver its patented prescription co-pilot platform for an additional six years, to September 22, 2031, while expanding the scope to nurses and pharmacists in all of Maccabi's nationwide pharmacies. Maccabi is the first in Israel and one of the first HMOs worldwide to offer an end-to-end safety coverage throughout the patient journey, allowing complete visibility to pharmacists in the pharmacies into clinician decision while prescribing patient centric medication. The expanded contract was changed from a fixed base contract to Seegnal's current SaaS based model based on Quarterly Recurring License Fees and is expected to generate additional revenue for the Corporation.

Keep reading...Show less
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc.  (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News